All Modules

This module focuses on Breast, endometrial and ovarian cancers (BEOC), which are among the most prevalent cancers affecting individuals assigned female at birth (IAFABP). Learners will explore the categories, pathophysiology, risk factors, symptoms, and treatment options for these cancers, noting that early symptoms, particularly for ovarian and endometrial cancers, can often go unnoticed, leading to a poorer prognosis. While common treatments can be effective, they frequently come with significant side effects that impact daily life and overall well-being. By the end of this module, learners will be able to explain the pathophysiology and symptomatology of BEO cancers, identify treatment options and their adverse effects, and discuss the therapeutic potential of medical cannabis for alleviating treatment-related side effects, including chemotherapy-induced nausea and vomiting (CINV). Additionally, the module will cover important considerations for selecting appropriate medical cannabis products and outline general conditions related to prescribing these treatments. Preview this module by watching the video above. Estimated Duration: 1 hour Access Duration: 12 months from date of purchase Learning Outcomes Upon completion of this module, you’ll be able to: Explain BEOC pathogenesis and pathophysiology Identify benefits and drawbacks of conventional interventions for BEOC Discuss medical cannabis’ therapeutic potential for treating BEOC symptoms and treatment-related side effects Identify considerations for selecting a medical cannabis product to treat symptoms of BEO cancers

This module explores the endocannabinoid system (ECS) and its critical role in the effects of medical cannabis. It examines the discoveries that shaped our understanding of the ECS, its primary components—such as CB1, CB2, and TRPV1 receptors—and the mechanisms of retrograde cell signaling, which underpins how cannabinoids influence physiological processes. Participants will learn about the role of ECS ligands and non-ligand mediators in cannabis pharmacology, the concept of endocannabinoid tone, and factors that can affect it. Clinical considerations are addressed to provide a deeper understanding of how the ECS informs the safe and effective use of medical cannabis in patient care. Preview this module by watching the video above. Estimated Duration: 1 hour Access Duration: 12 months from date of purchase Learning Outcomes Upon completion of this module, you’ll be able to: Describe the discoveries that shaped today's understanding of the endocannabinoid system (ECS) Explain the functions of the ECS, its main components, and how they interact Discuss the function and benefits of retrograde cell signalling Outline the roles and functions of cannabinoid receptors CB1 and CB2, and vanilloid receptor TRPV1 Identify ECS ligands and non-ligand mediators and describe their role in ECS function Define endocannabinoid tone and its influencing factors Discuss clinical considerations related to the ECS

This module explores the complexities of cancer, including its pathogenesis, common types, grading criteria, and contemporary treatment options. Learners will gain insights into the rising incidence of cancer in Australia and the significant advancements in survival rates, alongside the challenges posed by treatment side effects. A key focus will be the emerging role of medical cannabis, examining its therapeutic potential for alleviating cancer symptoms and mitigating treatment side effects, as well as its implications for palliative care. By the end of the module, learners will be equipped to explain cancer's biological mechanisms, identify various cancers and their treatments, and assess the benefits and risks of medical cannabis in cancer care. This knowledge aims to enhance understanding and support improved patient outcomes in the evolving landscape of cancer treatment. Preview this module by watching the video above. Estimated Duration: 1 hour Access Duration: 12 months from date of purchase Learning Outcomes Upon completion of this module, you’ll be able to: Explain the pathogenesis and pathophysiology of cancer Identify and describe the main types of cancers and tumours Identify and describe the common cancer-grading criteria Identify and explain contemporary cancer treatments, their benefits, risks and side effects Explain medical cannabis’ therapeutic potential for treating cancer symptoms and treatment side effects Identify risks associated with medical cannabis treatment for those with cancer Explain how medical cannabis may play a role in palliative care for those with cancer

Sixty-five-year-old Ryan is living with prostate cancer and is experiencing chronic pain and ongoing sleep disturbances. Despite undergoing chemotherapy and trialling several first-line medications, his symptoms have progressed, now significantly impacting his ability to manage daily activities without support. In this case study, we examine how Dr. Xie considered medical cannabis as part of a broader symptom management strategy. The module explores the rationale behind its use, the prescribing process, and the clinical considerations involved in supporting a patient like Ryan. Through this scenario, practitioners will engage with current evidence and frameworks for evaluating medical cannabis in the context of cancer-related symptom management, with attention to safety, patient suitability, and clinical outcomes. Preview this module by watching the video above. Estimated Duration: 1 hour Access Duration: 12 months from date of purchase Learning Outcomes Upon completion of this module, you’ll be able to: Explain the pathophysiology of prostate cancer and identify common management strategies  Discuss the potential benefits and limitations of medical cannabis as a treatment option for secondary symptoms of prostate cancer (e.g. pain and sleep disturbances) Identify suitable candidates for medical cannabis treatment Facilitate clinical discussions with patients around medical cannabis as a therapeutic option in the management of secondary symptoms of prostate cancer (e.g. pain and sleep disturbances) Devise treatment plans that consider patient safety and minimise risk

In the current landscape, medical cannabis products are tightly regulated with stringent dispensing requirements. Medical cannabis dispensers (MCDs), and the businesses they represent, are responsible for adhering to all relevant legislation and policy while also implementing best practice dispensing for robust patient-centred care. This fundamental module equips pharmacists with the knowledge and skills to effectively fulfil their essential role in dispensing medical cannabis.  Beyond the technical aspects, pharmacists serve as key advocates for patient care, ensuring the safety, privacy, and well-being of patients throughout their medical cannabis journey. In this module, learners will explore methods to build trust with patients, provide comprehensive education on cannabis products, and ensure compliance with record-keeping and reporting standards. This module also emphasises the critical role of collaboration with healthcare teams to ensure safer, more effective treatment outcomes. Preview this module by watching the video above. Estimated Duration: 1 hour Access Duration: 12 months from date of purchase Learning Outcomes Upon completion of this module, you’ll be able to: Identify the legal and ethical responsibilities of medical cannabis dispensers (MCDs) Implement respectful communication practices to educate and build safety, trust and rapport with patients Counsel patients on safe use of medical cannabis products – including dosage, titration, administration, storage and identifying and responding to side effects Explain how to store, monitor and maintain medical cannabis products securely Discuss pharmacists' record-keeping obligations when dispensing medical cannabis Collaborate with other health practitioners for a multidisciplinary approach to medical cannabis treatment

A person with ovaries is typically born with about one million ovarian follicles.¹ By puberty, this number decreases to between 250,000 and 400,000¹, continuing to decline throughout life. Between the ages of 45-56, the diminishing ovarian follicle count leads to hormonal shifts that can cause various symptoms, including irregular menstruation and vasomotor or organ-related issues.¹ This transitional phase is known as perimenopause, while menopause marks the final menstrual cycle. This module explores the potential of medical cannabis to alleviate disruptive symptoms associated with menopause, offering an alternative option for symptom management. Preview this module by watching the video above. Estimated Duration: 1 hour Access Duration: 12 months from date of purchase Learning Outcomes Upon completion of this module, you’ll be able to: Explain the physiology, symptomatology and effects of menopause Identify conventional interventions for symptoms of menopause and describe their potential strengths and drawbacks Discuss medical cannabis' mechanisms of action and therapeutic potential for treating symptoms of menopause Identify considerations and risks for selecting medical cannabis products to treat symptoms of menopause References ¹ Peacock, Kimberly, and Kari M. Ketvertis. “Menopause.” NIH, StatPearls Publishing, Jan. 2024, www.ncbi.nlm.nih.gov/books/NBK507826/. Accessed 26 June 2024.

Emotional fluctuations after childbirth are common and typically subside within two weeks.¹ However, when these symptoms persist and interfere with a person's ability to care for themselves or their infant, it may indicate postpartum depression (PPD).¹ Affecting an estimated 6-12% of Australian women², PPD is widespread, yet many hesitate to seek treatment due to concerns around privacy³, fear of judgement, and a lack of adequate support⁴. Even when treatment is sought, conventional options often fall short in fully addressing the symptoms. This module explores the potential role of medical cannabis in helping individuals with PPD, offering an alternative path toward symptom relief. Preview this module by watching the video above. Estimated Duration: 1 hour Access Duration: 12 months from date of purchase Learning Outcomes Upon completion of this module, you’ll be able to: Explain the pathophysiology, symptomatology and effects of PPD Identify conventional interventions for PPD and describe their potential strengths and drawbacks Discuss medical cannabis' mechanisms of action and therapeutic potential for treating symptoms of PPD (e.g. pain, low mood, anxiety and sleep problems) Identify considerations and risks for selecting medical cannabis products to treat PPD References ¹ Mughal, Saba, et al. “Postpartum Depression.” PubMed, StatPearls Publishing, Jan. 2023, www.ncbi.nlm.nih.gov/books/NBK519070. Accessed 17 June 2024. ² Ogbo, Felix Akpojene, et al. “Determinants of Antenatal Depression and Postnatal Depression in Australia.” BMC Psychiatry, vol. 18, no. 1, Feb. 2018, https://doi.org/10.1186/s12888-018-1598-x. Accessed 17 June 2024. ³ Brummelte, Susanne, and Liisa A. M. Galea. “Postpartum Depression: Etiology, Treatment and Consequences for Maternal Care.” Hormones and Behavior, vol. 77, Jan. 2016, pp. 153–66, https://doi.org/10.1016/j.yhbeh.2015.08.008. Accessed 17 June 2024. ⁴ Zauderer, Cheryl. “Postpartum Depression: How Childbirth Educators Can Help Break the Silence.” Journal of Perinatal Education, vol. 18, no. 2, Jan. 2009, pp. 23–31, https://doi.org/10.1624/105812409x426305. Accessed 17 June 2024.

Premenstrual dysphoric disorder (PMDD) is a complex and disabling condition¹ marked by cognitive, emotional, and physical symptoms in the lead-up to menstruation². Affecting an estimated 3-8% of menstruating individuals³, with 5-8% experiencing severe distress or significant impairment in daily activities⁴, PMDD remains a challenging condition to manage. Without a clear cause, current treatments focus on symptomatic control—targeting mood regulation or hormonal balance—though many patients find limited relief. This module explores the potential of medical cannabis as a therapeutic option for resistant PMDD symptoms, offering a non-hormonal alternative to traditional treatments that may carry reproductive side effects. Preview this module by watching the video above. Estimated Duration: 1 hour Access Duration: 12 months from date of purchase Learning Outcomes Upon completion of this module, you’ll be able to: Explain the pathophysiology, symptomatology and effects of PMDD Identify conventional interventions for PMDD and describe their potential strengths and drawbacks Discuss medical cannabis' mechanisms of action and therapeutic potential for treating symptoms of PMDD (e.g. pain, low mood, anxiety and sleep problems) Identify considerations and risks for selecting medical cannabis products to treat PMDD References ¹ Osborn, Elizabeth, et al. “Women’s Experiences of Receiving a Diagnosis of Premenstrual Dysphoric Disorder: A Qualitative Investigation.” BMC Women’s Health, vol. 20, no. 1, Oct. 2020, https://doi.org/10.1186/s12905-020-01100-8. Accessed 26 June 2024. ² Hantsoo, Liisa, and C. Neill Epperson. “Premenstrual Dysphoric Disorder: Epidemiology and Treatment.” Current Psychiatry Reports, vol. 17, 2015, https://doi.org/10.1007/s11920-015-0628-3. Accessed 26 June 2024. ³ Halbreich, Uriel, et al. “The Prevalence, Impairment, Impact, and Burden of Premenstrual Dysphoric Disorder (PMS/PMDD).” Psychoneuroendocrinology, vol. 28, no. 3, Aug. 2003, pp. 1–23, https://doi.org/10.1016/s0306-4530(03)00098-2. Accessed 26 June 2024. ⁴ Slavin, Melissa, et al. “Cannabis and Symptoms of PMS and PMDD.” Addiction Research & Theory, vol. 25, no. 5, Mar. 2017, pp. 383–89, https://doi.org/10.1080/16066359.2017.1294165. Accessed 26 June 2024.

Polycystic ovarian syndrome (PCOS) is the most common endocrine disorder¹ , affecting 12-21% of women of reproductive age.² Despite its widespread occurrence, only 30% of those with PCOS are diagnosed², often only when complications begin to severely impact their quality of life.³ This module explores the potential of medical cannabis as an adjunct treatment for PCOS, offering new hope for managing symptoms and improving patient outcomes. Preview this module by watching the video above. Estimated Duration: 1 hour Access Duration: 12 months from date of purchase Learning Outcomes Upon completion of this module, you’ll be able to: Explain the pathophysiology, symptomatology and effects of PCOS Identify conventional interventions for PCOS and describe their potential strengths and drawbacks Discuss medical cannabis' mechanisms of action and therapeutic potential for treating symptoms of PCOS (e.g. pain, low mood, anxiety and sleep problems) Identify considerations and risks for selecting medical cannabis products to treat PCOS References ¹ Amiri, Fatemeh Nasiri, et al. “The Experience of Women Affected by Polycystic Ovary Syndrome: A Qualitative Study from Iran.” International Journal of Endocrinology and Metabolism, vol. 12, no. 2, Apr. 2014, https://doi.org/10.5812/ijem.13612. Accessed 26 June 2024. ² Boyle, Jacqueline, and Helena J. Teede. “Polycystic Ovary Syndrome.” Australian Family Physician, vol. 41, no. 10, Oct. 2012, www.racgp.org.au/afp/2012/october/polycystic-ovary-syndrome. Accessed 26 June 2024. ³ Singh, Samradhi, et al. “Polycystic Ovary Syndrome: Etiology, Current Management, and Future Therapeutics.” Journal of Clinical Medicine, vol. 12, no. 4, Feb. 2023, p. 1454, https://doi.org/10.3390/jcm12041454. Accessed 26 June 2024.

Endometriosis, a condition marked by the growth of endometrial tissue outside the uterus, causes severe and debilitating symptoms, making it the leading cause of chronic pelvic pain. Affecting 1 in 9 people assigned female at birth¹, endometriosis accounted for over 3,600 emergency department visits in 2021-2022 alone². Despite its prevalence, current treatment options are often invasive and carry significant health risks. This module explores the potential of medical cannabis as an alternative treatment for endometriosis, offering symptom relief with fewer side effects. Preview this module by watching the video above. Estimated Duration: 1 hour Access Duration: 12 months from date of purchase Learning Outcomes Upon completion of this module, you’ll be able to: Explain the pathophysiology, symptomatology and effects of endometriosis Identify conventional interventions for endometriosis and describe their potential strengths and drawbacks Discuss medical cannabis' mechanisms of action and therapeutic potential for treating symptoms of endometriosis (e.g. pain, low mood, anxiety, sleep problems and nausea) Identify considerations and risks for selecting medical cannabis products to treat endometriosis References ¹ Armour, M., Ciccia, D., Yazdani, A., Rombauts, L., Niekerk, L. V., Schubert, R., & Abbott, J. (2023). Endometriosis research priorities in Australia. Australian and New Zealand Journal of Obstetrics and Gynaecology ,  63 (4), 594-598. https://doi.org/https://doi.org/10.1111/ajo.13699  ² “Endometriosis, Emergency Department Presentations.” Australian Institute of Health and Welfare, 14 Dec. 2023, www.aihw.gov.au/reports/chronic-disease/endometriosis-in-australia/contents/treatment-management/ed-presentations. Accessed 26 June 2024.

Dysmenorrhoea, characterised by painful cramping in the lower abdomen or back during menstruation, affects 88% of menstruating Australians aged 16-291. Despite being the most common gynaecological condition in menstruating years, it is often inadequately treated, leaving many with diminished quality of life. This module examines the potential of medical cannabis as a therapeutic option for dysmenorrhoea, offering symptom relief with potentially fewer side effects than conventional treatments. Preview this module by watching the video above. Estimated Duration: 1 hour Access Duration: 12 months from date of purchase Learning Outcomes Upon completion of this module, you’ll be able to: Explain the pathophysiology, symptomatology and effects of primary dysmenorrhoea Identify conventional interventions for primary dysmenorrhoea and describe their potential strengths and drawbacks Discuss medical cannabis' mechanisms of action and therapeutic potential for treating symptoms of primary dysmenorrhoea (e.g. pain, low mood, anxiety, sleep problems, and nausea and vomiting) Identify considerations and risks for selecting medical cannabis products to treat primary dysmenorrhoea References ¹ Subasinghe, Asvini K., et al. “Prevalence and Severity of Dysmenorrhoea, and Management Options Reported by Young Australian Women.” Australian Family Physician, vol. 45, no. 11, Nov. 2016, pp. 829–34, pubmed.ncbi.nlm.nih.gov/27806454/. Accessed 26 June 2024.

Estimated to affect over a billion people globally, hepatitis is a major global health crisis. Characterised by inflammation of the liver, hepatitis is responsible for severe consequences including liver damage, failure and death.¹ But it is preventable and treatable. The World Health Organisation (WHO) and its member states (including Australia) have pledged to reduce hepatitis infections by 90% and hepatitis B and C related deaths by 65% by 2030 through vaccination, diagnostic testing, medication, and educational initiatives.¹‚² The use of medical cannabis in the treatment of hepatitis symptoms is a relatively new and evolving area of research, with findings that have sometimes been contradictory. While more research is needed to reach definitive conclusions, early evidence suggests that medical cannabis may have the potential to improve the quality of life for those living with hepatitis by addressing primary and secondary symptoms. Preview this module by watching the video above. Estimated Duration: 1 hour Access Duration: 12 months from date of purchase Learning Outcomes Upon completion of this module, you’ll be able to: Describe the prevalence, pathogenesis, pathophysiology, symptoms and impacts of, and diagnostic methods for hepatitis and its subtypes Identify common hepatitis treatment interventions and explain their pharmacology Explain how medical cannabis treatment may benefit people with hepatitis Identify and explain potential risks and clinical considerations when recommending medical cannabis treatment for people with hepatitis References ¹ World Health Organisation. Hepatitis. www.who.int. Published 2024. Accessed August 30, 2024. https://www.who.int/health-topics/hepatitis/elimination-of-hepatitis-by-2030 ² Coalition for Global Hepatitis Elimination. About Hepatitis Elimination. CGHE. Accessed August 30, 2024. https://www.globalhep.org/about/about-hepatitis-elimination#:~:text=In%202016%2C%20the%20World%20Health

Peter, a 45-year-old with human immunodeficiency virus (HIV), is experiencing anxiety and insomnia as side effects of his current treatment regime. These side effects have caused Peter to feel significant fatigue, and he now finds it difficult to leave the house to participate in his regular social and community activities. In this case study, we explore how Dr. Xie prescribed medical cannabis products in addition to Peter’s current treatment regime to help manage his symptoms and get him out and about once more. Preview this module by watching the video above. Estimated Duration: 1 hour Access Duration: 12 months from date of purchase Learning Outcomes Upon completion of this module, you’ll be able to: Explain the pathophysiology of Human immunodeficiency virus (HIV) and identify common management strategies  Discuss the potential benefits and limitations of medical cannabis as a treatment option for symptoms of HIV Identify suitable candidates for medical cannabis treatment Facilitate clinical discussions with patients around medical cannabis as a therapeutic option in the management of symptoms of HIV Devise treatment plans that consider patient safety and minimise risk

Nickolas, a 65-year-old with motor neurone disease (MND), seeks treatment for his pain, stress, anxiety and depression. Despite trialling a range of treatment options, and consulting with several specialists, Nickolas is still experiencing primary and secondary symptoms that impact his quality of life. In this case study, we explore how Xie prescribed a medical cannabis product to help manage Nickolas’ symptoms, so he could mobilise with less pain and improve his psychological wellbeing. Preview this module by watching the video above. Estimated Duration: 1 hour Access Duration: 12 months from date of purchase Learning Outcomes Upon completion of this module, you’ll be able to: Explain the pathophysiology of Motor Neurone Disease (MND) and identify common management strategies  Discuss the potential benefits and limitations of medical cannabis as a treatment option for symptoms of MND Identify suitable candidates for medical cannabis treatment Facilitate clinical discussions with patients around medical cannabis as a therapeutic option in the management of symptoms of MND Devise treatment plans that consider patient safety and minimise risk Offer effective patient education and treatment advice on the therapeutic use of medical cannabis

This module explores the growing interest in medical cannabis as a therapeutic option for managing autoimmune symptoms like pain and inflammation.  Autoimmune diseases occur when the immune system mistakenly attacks the body's own cells, leading to chronic conditions. Despite their prevalence, their causes remain unclear.  With some traditional treatments, such as NSAIDs and opioids, causing risks to health and wellbeing, emerging research suggests that medical cannabis may be a viable complement or alternative for managing pain and inflammation.  This module offers an overview of autoimmunity, explaining the theorised pathophysiology, symptoms, impacts, diagnostics, and conventional treatments for common presentations, and explores contemporary research findings explaining how medical cannabis may help to manage these symptoms and improve quality of life for people with autoimmune disease. Preview this module by watching the video above. Estimated Duration: 1.25 hours Access Duration: 12 months from date of purchase Learning Outcomes Upon completion of this module, you’ll be able to: Describe the immune system, its purpose, components and key actors Describe the purpose, functions and actors of the innate and adaptive systems Describe autoimmunity, including its causes and effects Explain how autoreactivity can cause autoimmune responses Identify causes, symptoms and impacts of common autoimmune diseases Describe common diagnostic methods for autoimmune disease Describe conventional treatments for autoimmune disease, and some side effects and drawbacks With reference to research, analyse how medical cannabis may assist in autoimmune disease symptom management

Fibromyalgia (FMS) is a heterogeneous condition characterised by chronic pain throughout the body and is commonly associated with a range of other conditions and symptoms. It’s estimated that there are 1 million Australians with FMS and it’s more common in women than men. In this case study, Jordan, a 32-year-old with FMS, seeks treatment for anxiety and chronic pain. Jordan experienced pain relief while medicated in hospital, but since then hasn't found a solution. The pain and stress is beginning to impact their sleep and daily living.  In this case study, we explore how Jordan was prescribed medical cannabis oil products to help them manage their symptoms and improve their quality of life. Preview this module by watching the video above. Estimated Duration: 1 hour Access Duration: 12 months from date of purchase Learning Outcomes Upon completion of this module, you’ll be able to: Explain the pathophysiology of fibromyalgia and identify common management strategies Discuss the potential benefits and limitations of medical cannabis as a treatment option for common symptoms of fibromyalgia  Identify suitable candidates for medical cannabis treatment Devise treatment plans that consider patient safety and minimise risk Offer effective patient education and treatment advice on the therapeutic use of medical cannabis